公开(公告)号：US20250154526A1

公开(公告)日：2025-05-15

申请号：US18684984

申请日：2022-08-18

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Anna Nikolaevna STRELKOVA ,  Sergei Aleksandrovich LEGOTSKII ,  Tatiana Evgenievna SHUGAEVA ,  Pavel Mikhailovich GERSHOVICH ,  Alexandr Anatolevich NADOLINSKII ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  G16B20/50 ,  G16B30/10

Abstract: The present application relates to the fields of gene therapy and molecular biology. More specifically, the present invention relates to a method for producing a modified adeno-associated virus (AAV) capsid and to a modified AAV capsid produced by said method, as well as to an isolated nucleic acid encoding said modified capsid and a vector based on recombinant adeno-associated virus for delivering a heterologous nucleic acid sequence to a subject, which includes said modified capsid.

公开(公告)号：US20230321220A1

公开(公告)日：2023-10-12

申请号：US18043354

申请日：2021-08-27

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Alexander Vladimirovich PROKOFYEV ,  Pavel Mikhailovich GERSHOVICH ,  Anna Nikolaevna STRELKOVA ,  Natalia Aleksandrovna SPIRINA ,  Diana Aleksandrovna KONDINSKAIA ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12

CPC classification number: A61K39/215 ,  C12N15/86 ,  C07K14/005 ,  C07K14/61 ,  A61P31/12 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071 ,  C12N2750/14143 ,  A61K2039/5256

Abstract: The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to a nucleic acid that encodes RBD-S of SARS-CoV-2, to an expression cassette and a vector based thereon, as well as to a recombinant AAV5 (adeno-associated vims serotype 5)-based virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

公开(公告)号：US20220112286A1

公开(公告)日：2022-04-14

申请号：US17417686

申请日：2020-02-20

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Dmitry Borisovich STAROVEROV ,  Anna Valentinovna EVSTRATEVA ,  Alexey Konstantinovich MISORIN ,  Timofey Aleksandrovich NEMANKIN ,  Mariia Aleksandrovna SHCHEMELEVA ,  Anna Konstantinovna VLADIMIROVA ,  Arina Vitalevna ANIKINA ,  Roman Alekseevich IVANOV ,  Dmitry Valentinovich MOROZOV ,  Pavel Andreevich IAKOVLEV ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US20220089761A1

公开(公告)日：2022-03-24

申请号：US17288234

申请日：2019-10-30

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Pavel Andreevich IAKOVLEV ,  Natalia Eugenievna PESTOVA ,  Arina Vitalevna ANIKINA ,  Anna Alexandrovna TRUDOVISHNIKOVA ,  Mariia Aleksandrovna SHCHEMELEVA ,  Nina Grachyaevna KHARATIAN ,  Valery Vladimirovich SOLOVYEV ,  Alexey Konstantinovich MISORIN ,  Sergei Vasilyevich DIDUK ,  Anna Vladimirovna EROSHOVA ,  Veronika Sergeevna USATOVA ,  Elena Andreevna KRENDELEVA ,  Iakov Iurevich USTIUGOV ,  Aleksei Aleksandrovich ALEKSANDROV ,  Iana Andreevna SMIRNOVA ,  Svetlana Vladimirovna KOSKOVA ,  Roman Alekseevich IVANOV ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/63

Abstract: The present invention relates to biotechnology and provides a monoclonal antibody that specifically binds to CD20. The invention also relates to DNA encoding said antibody, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using said antibody.

公开(公告)号：US20210332120A1

公开(公告)日：2021-10-28

申请号：US16097562

申请日：2016-12-02

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Dmitry Valentinovich MOROZOV ,  Andrei Borisovich ULITIN ,  Ekaterina Sergeevna ZUBAREVA ,  Iakov Iurevich USTIUGOV ,  Aleksandr Vladimirovich KARABELSKII ,  Dmitry Valeryevich KORZHAVIN ,  Tatiana Veniaminovna CHERNOVSKAYA ,  Aleksandr Valerevich GRACHEV ,  Yury Ivanovich BASOVSKIY ,  Ekaterina Aleksandrovna LOMKOVA ,  Veronika Sergeevna USATOVA ,  Aleksei Aleksandrovich ALEKSANDROV ,  Elena Leonidovna MOROZOVA ,  Roman Alekseevich IVANOV ,  Pavel Andreevich IAKOVLEV

IPC: C07K16/24 ,  A61P19/02 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to the field of biotechnology and provides monoclonal tri-specific binding molecules that specifically bind to human IL-17A, human IL-17F, and a human pro-inflammatory molecule (in particular, TNFα) with high affinity. The invention also relates to DNA constructs encoding said binding molecules, related expression vectors and methods of production, and methods of treatment using said binding molecules.

公开(公告)号：US20220056133A1

公开(公告)日：2022-02-24

申请号：US17417570

申请日：2019-12-24

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Olga Vladimirovna BRITANOVA ,  Dmitry Borisovich STAROVEROV ,  Anna Valentinovna EVSTRATEVA ,  Alexey Konstantinovich MISORIN ,  Timofey Aleksandrovich NEMANKIN ,  Mariia Aleksandrovna SHCHEMELEVA ,  Anna Konstantinovna VLADIMIROVA ,  Arina Vitalevna ANIKINA ,  Roman Alekseevich IVANOV ,  Dmitry Valentinovich MOROZOV ,  Pavel Andreevich IAKOVLEV ,  Sergey Anatolievich LUKYANOV

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

公开(公告)号：US20210246138A1

公开(公告)日：2021-08-12

申请号：US17264670

申请日：2019-07-31

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Aleksei Leonidovich MINDICH ,  Anna Jur'evna CHESTNOVA ,  Mariia Andreevna KASATKINA ,  Andrei Ivanovich ALAFINOV ,  Aleksei Sergeevich GAVRILOV ,  Anton Aleksandrovich EVDOKIMOV ,  Liliana Vyacheslavovna LENSHMIDT ,  Elena Aleksandrovna MAKSIMENKO ,  Mariia Sergeevna MISHINA ,  Sergei Aleksandrovich SILONOV ,  Evgenii Jur'evich SMIRNOV ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: C07D471/04 ,  A61P35/00

Abstract: The present invention relates to novel compounds of formula I: which have the properties of CDK8/19 inhibitors, to a pharmaceutical composition comprising said compounds, and to use thereof as a medicine for treating diseases and disorders.

公开(公告)号：US20200369771A1

公开(公告)日：2020-11-26

申请号：US16605865

申请日：2018-04-11

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Andrey Borisovich ULITIN ,  Victoria Mikhailovna EKIMOVA ,  Ekaterina Vladimirovna SOFRONOVA, ,  Yulia Sergeevna CHERNYKH ,  Sergei Andreevich AGEEV ,  Anna Konstantinovna VLADIMIROVA ,  Aleksei Aleksandrovich ALEKSANDROV ,  Pavel Alekseevich GREBNEV ,  Valery Vladimirovich SOLOVYEV ,  Iakov Iurevich USTIUGOV ,  Pavel Andreevich IAKOVLEV ,  Timofey Aleksandrovich NEMANKIN ,  Dmitry Valentinovich MOROZOV

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to the field of biotechnology and provides antibodies that specifically binds to PD-L1. The invention also relates to DNA encoding said antibodies, to corresponding expression vectors and to methods of producing, and to methods of treatment using said antibodies.

公开(公告)号：US20250127923A1

公开(公告)日：2025-04-24

申请号：US18684921

申请日：2022-08-21

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Anna Nikolaevna STRELKOVA ,  Sergei Aleksandrovich LEGOTSKII ,  Tatiana Evgenievna SHUGAEVA ,  Pavel Mikhailovich GERSHOVICH ,  Alexander Vladimirovich PROKOFYEV ,  Mariya Pavlovna PEREPELKINA ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K48/00 ,  C07K14/005 ,  C12N15/86

Abstract: The present application relates to the fields of gene therapy and molecular biology. More specifically, the present invention relates to an isolated modified capsid protein VP1 from adeno-associated virus serotype 5 (AAV5), comprising one or more amino acid substitutions compared to the wild-type AAV5 capsid protein VP1, which substitutions increase the efficiency of transduction, increase the efficiency of packaging of AAV viral genomes with rAAV5-based products, and also increase the efficiency of production (assembly) of a vector based on recombinant adeno-associated virus serotype 5 (rAAV5), to a capsid and a vector based on the above VP1, as well as to uses thereof.

公开(公告)号：US20240350663A1

公开(公告)日：2024-10-24

申请号：US18684886

申请日：2022-08-21

Applicant: JOINT STOCK COMPANY "BIOCAD"

Inventor： Anna Nikolaevna STRELKOVA ,  Tatiana Evgenievna SHUGAEVA ,  Pavel Mikhailovich GERSHOVICH ,  Pavel Andreevich IAKOVLEV ,  Dmitry Valentinovich MOROZOV

IPC: A61K48/00 ,  C07K14/005 ,  C12N15/86

CPC classification number: A61K48/0041 ,  C07K14/005 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: The present application relates to the fields of gene therapy and molecular biology. More specifically, the present invention relates to an isolated modified capsid protein VP1 from adeno-associated virus serotype 9 (AAV9) comprising one or more amino acid substitutions compared to the wild-type AAV9 capsid protein VP1, which substitutions increase the efficiency of production (assembly) of the vector based on recombinant adeno-associated virus serotype 9 (rAAV9), to a capsid and a vector based on the above VP1, as well as to uses thereof.